Table 1.
Demographic and clinical characteristics of COVID-19 patients in melatonin and control groups.
| Patient characteristics | All patients (n=158) | Control group (n=76) | Melatonin group (n=82) | df | P-value |
|---|---|---|---|---|---|
| Age (mean±SD) | 56.3±7.7 | 55.7±8.0 | 56.8±7.5 | . | 0.393 ͣ |
| Gender | |||||
| Male, n (%) | 114 (72.2%) | 56 (73.7%) | 58 (70.7%) | 1 | 0.725° |
| Female, n (%) | 44 (27.8%) | 20 (26.3%) | 24 (29.3%) | ||
| Other comorbidities Hypertension | |||||
| 84 (53.2%) | 34 (44.7%) | 50 (61.0%) | 1 | 0.055° | |
| Ischemic heart disease | 25 (15.8%) | 10 (13.2%) | 15 (18.3%) | 0.394° | |
| 47 (29.7%) | 22 (28.9%) | 25 (30.5%) | 0.863° | ||
| Diabetes mellitus | |||||
| Asthma | 16 (10.1%) | 11 (14.5%) | 5 (6.1%) | 0.113° |
df, degree of freedom; SD, standard deviation; n, number of patients; %, percentage of patients in each group; °, no significant difference (P > 0.05) using Chi-square test; ͣ, no significant difference (P > 0.05) using Mann-Whitney U test